UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14C

Information Statement Pursuant to Section 14(c)
of the Securities Exchange Act of 1934

FILED BY THE REGISTRANT [X]

FILED BY PARTY OTHER THAN THE REGISTRANT [ ]

CHECK THE APPROPRIATE BOX:

[ ] Preliminary Information Statement
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
14c-5(d)(2))
[X] Definitive Information Statement

Ridgefield Acquisition Corp.
------------------------------------------------
(Name of Registrant as specified in its charter)

PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):

[X] No fee required.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transactions applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to exchange act rule 0-11:
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:

[ ] Fee paid previously with preliminary materials.

[ ] Check box if any part of the fee is offset as provided by exchange
act rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration
statement number, or the form or schedule and the date of its filing.
(1) Amount previously paid:
(2) Form, schedule or registration statement no.: DEF SCH 14C
(3) Filing party: Ridgefield Acquisition Corp.
(4) Date filed: May 26, 2006

RIDGEFIELD ACQUISITION CORP.
100 Mill Plain Road
Danbury, Connecticut 06811
Telephone (203) 791-3871

May 26, 2006

Dear Shareholder:

The purpose of the attached Information Statement is to inform the shareholders
of record of Ridgefield Acquisition Corp. as of the close of business on April
28, 2006 (the "Record Date"), that the Board of Directors has declared a special
stock dividend for the purposes of spinning off Bio-Medical Automation, Inc.,
which is wholly owned by Ridgefield Acquisition Corp., to the shareholders of
Ridgefield Acquisition Corp. (the "Spin-off"). The Spin-off will be on a pro
rata basis of one share of Bio-Medical Automation, Inc. for each share of
Ridgefield Acquisition Corp. held as of April 28, 2006. Shareholder approval for
the Spin-off is not required.

WE ARE NOT ASKING YOU FOR A PROXY
AND YOU ARE REQUESTED NOT TO SEND A PROXY

If you are an owner of common stock of Ridgefield Acquisition Corp. on the
Record Date, then on the effective date of the Spin-off, you will own shares in
both Ridgefield and Bio-Medical Automation, Inc.

The enclosed Information Statement is being sent to all shareholders of
Ridgefield Acquisition Corp. as of the Record Date, to provide our shareholders
and the public, information about the Spin-off and Bio-Medical Automation, Inc.,
including its plan of operation, capitalization, management and pro forma
financial statements. We suggest you read the Information Statement carefully.

The securities of Bio-Medical Automation, Inc. being issued to our shareholders
are restricted securities that have not been registered with the U.S. Securities
and Exchange Commission and/or any state securities regulator. All certificates
representing Bio-Medical Automation, Inc. common stock to be issued pursuant to
the special stock dividend will contain a legend stating that the securities
have not been registered and that such securities may not be transferred or sold
absent registration or the availability of an exemption from registration.

Enclosed with this Information Statement is a copy of the Annual Report of
Ridgefield Acquisition Corp. on Form 10-KSB for the year ended December 31,
2005.

We appreciate your continued interest in Ridgefield Acquisition Corp.

By Order of the Board of Directors

/s/ Steven N. Bronson

----------------------------
Steven N. Bronson, Chairman

RIDGEFIELD ACQUISITION CORP.
100 MILL PLAIN ROAD
DANBURY, CONNECTICUT 06811
TELEPHONE (203) 791-3871

INFORMATION STATEMENT
PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934

AS OF MAY 26, 2006

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND A PROXY

This Information Statement is being furnished to the shareholders of record as
of April 28, 2006 (the "Record Date") of Ridgefield Acquisition Corp., a
Colorado corporation (the "Company" or "Ridgefield"), in connection with the
action taken by Ridgefield's Board of Directors on April 18, 2006, to issue a
special dividend of 100% of the outstanding shares of its wholly owned
subsidiary Bio-Medical Automation, Inc., a Nevada corporation ("Bio-Medical") to
its shareholders of record on the Record Date (the "Spin-off").

Shares of Bio-Medical common stock will be issued, as a special stock dividend,
to shareholders of Ridgefield common stock as of the close of business on the
Record Date. These shareholders will receive one share of Bio-Medical common
stock for every one share of Ridgefield common stock held as of the Record Date.
The Spin-off will be effective no sooner than the 20th day after the mailing of
this Information Statement to our shareholders.

No shareholder approval of the Spin-off is required or sought. Ridgefield
shareholders will not be required to pay for the shares of Bio-Medical common
stock to be received by them in the Spin-off, or to surrender or exchange shares
of Ridgefield common stock in order to receive the stock dividend of Bio-Medical
common stock or to take any other action in connection with the Spin-off. There
is no current trading market for Bio-Medical common stock.

The shares of Bio-Medical common stock being issued to the shareholders of
Ridgefield have not been registered under the Securities Act of 1933 or the
Securities Exchange Act of 1934 or any state laws. Neither the Securities and
Exchange Commission nor any state securities commission has approved or
disapproved the securities of Bio-Medical or determined if this Information
Statement is truthful or complete. Any representation to the contrary is a
criminal offense.

This Information Statement does not constitute an offer to sell or the
solicitation of an offer to buy any securities.

The date of this Information Statement is May 26, 2006, and it is first being
mailed to shareholders of Ridgefield Acquisition Corp. on or about May 30, 2006.

Questions and Answers about the Spin-Off

What is the Spin-off?

In the Spin-off, the Company will distribute to its shareholders as of the
Record Date all of the shares of our common stock of Bio-Medical Automation,
Inc. as a special stock dividend. Following the Spin-off, Bio-Medical will be a
separate company from Ridgefield, and Ridgefield will not have any ownership
interest in Bio-Medical. The number of shares of Ridgefield common stock you own
will not change as a result of the Spin-off.

What is the record date for the Spin-off?

The Record Date for the Spin-off is April 28, 2006, 5:00 p.m. (Eastern Time).

What do shareholders need to do to participate in the Spin-off?

Nothing, you are not required to take any action to receive Bio-Medical common
stock in the Spin-off, although you must have been a Ridgefield shareholder as
of the close of business on the Record Date of April 28, 2006. We urge you to
read this entire document carefully. No shareholder approval of the Spin-off is
required by applicable law, and we are not seeking shareholder approval of the
Spin-off.

Do I have to pay anything for the Bio-Medical stock?

No. You do not have to pay anything to receive the Bio-Medical common stock
pursuant to the Spin-off. The Spin-off is in effect a dividend of certain
property owned by Ridgefield to its shareholders.

Do I have to send in my Ridgefield stock certificate?

No. You do not have to do anything to receive the Bio-Medical stock. If you are
a Ridgefield shareholder as of the Record Date of the Spin-off, you will
automatically receive the stock dividend of Bio-Medical common stock.

How much Bio-Medical stock will I receive?

You will receive one share of Bio-Medical common stock for each share of
Ridgefield stock you own as of the Record Date.

When will the Spin-off be effective?

The shares of Bio-Medical common stock held by the Company will be issued to
shareholders of the Company no sooner than 20 days after the mailing of this
Information Statement to the Company's shareholders and the effectiveness of
Bio-Medical's registration statement on Form 10-SB (the "Spin-off Date").

Will I get a stock certificate?

Yes. You will receive a stock certificate representing your shares of
Bio-Medical common stock. The stock certificate will retain a restrictive legend
that states that the shares of Bio-Medical common stock have not been registered
under the Securities Act of 1933 and that such shares may not be assigned, sold,
transferred or conveyed absent registration or an exemption from registration.

Will my Ridgefield stock continue to be publicly traded?

Yes. The Ridgefield common stock will continue to be traded on the NASDAQ OTCBB
under the symbol "RDGA".

Do I have dissenter's rights or appraisal rights?

No. Holders of Ridgefield common stock are not entitled to any dissenter's
rights or appraisal rights in connection with the Spin-off.

Who is the transfer agent for Bio-Medical's common stock?

Atlas Stock Transfer Corporation
5899 S State Street
Salt Lake City, Utah 84107
Telephone (801)266-7151

Where can Ridgefield shareholders get more information?

You should direct inquiries concerning Ridgefield, the Spin-off and or
Bio-Medical to:

Ridgefield Acquisition Corp.
Attn: Steven N. Bronson, President
100 Mill Plain Road
Danbury, Connecticut
Telephone (203)791-3871

After the Spin-off, you should direct inquiries concerning Bio-Medical to:

Bio-Medical Automation, Inc.
Attn: Steven N. Bronson, President
100 Mill Plain Road
Danbury, Connecticut

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this information statement that are not historical facts,
but rather reflect Bio-Medical's current expectations concerning future results
and events constitute forward-looking statements. The words "believes,"
"expects," "intends," "plans," "anticipates," "intend," "estimate," "potential,"
"continue," "hopes," "likely," "will," and similar expressions, or the negative
of these terms, identify such forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties and other important
factors that could cause the actual results, performance or achievements of
Bio-Medical, or industry results, to differ materially from future results,
performance or achievements expressed or implied by such forward-looking
statements.

Readers are cautioned not to place undue reliance on these forward-looking
statements, which reflect management's view only as of the date of this
information statement. Bio-Medical undertakes no obligation to update the result
of any revisions to these forward-looking statements which may be made to
reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events, conditions or circumstances.

INFORMATION CONCERNING RIDGEFIELD ACQUSITION CORP.

Ridgefield was incorporated in the State of Colorado in 1983. Ridgefield is
engaged in, among other things, seeking to arrange for a merger, acquisition,
business combination or other arrangement by and between the Company and a
viable operating entity.

For information concerning Ridgefield's plan of operation, capitalization,
management and financial statements, readers are referred to Ridgefield's Annual
Report on Form 10-KSB for the year ended December 31, 2005, including
Ridgefield's audited consolidated financial statements, a copy of which is
enclosed herewith and incorporated herein by reference.

INFORMATION CONCERNING BIO-MEDICAL

On March 19, 2002, Ridgefield was awarded United States Patent No. US 6,358,749
B1 for the "Automated System for Chromosome Microdissection and Method of Using
Same" (the "Patent"). The Patent covers an automated system and method for
microdissection of samples such as chromosomes or other biological material, and
in particular, it relates to a robotic assisted microdissection system and
method that significantly reduces the time and skill needed for cellular and
sub-cellular dissections. Microdissection is defined as dissection under the
microscope; specifically: dissection of cells and tissues by means of fine
needles that are precisely manipulated by levers. The system and method covered
by the Patent attempts to provide reliability and ease of operation thereby
making microdissection widely available to laboratories.

During the first quarter of 2003, the Board of Directors of Ridgefield
authorized the formation of a wholly owned subsidiary of Ridgefield for the
purposes of owning, developing and exploiting the Patent. On March 3, 2003,
Ridgefield filed Articles of Incorporation with the Secretary of State of the
State of Nevada to form Bio-Medical Automation, Inc., a Nevada corporation
wholly owned by Ridgefield. The Board of Directors of Ridgefield authorized
management of Ridgefield to transfer the Patent to the Subsidiary in exchange
for 5,000,000 shares of the common stock of Bio-Medical. The transfer of the
Patent to Bio-Medical became effective in the quarter ended June 30, 2003.
Bio-Medical's Articles of Incorporation and bylaws are attached to Ridgefield's
Annual Report of Form 10-KSB for the fiscal year ended December 31, 2005 as
Exhibit 3.6 and Exhibit 3.7, respectively.

Following the Spin-off, Bio-Medical and Ridgefield will operate independently,
and neither will have any stock ownership, beneficial or otherwise, in the
other.

Description of Bio-Medical's Business

Bio-Medical has never derived any revenues from the technology covered by the
Patent and there can be no assurances that Bio-Medical will be able to derive
any revenues from the exploitation of the Patent. Bio-Medical will attempt to
research and develop a commercial application for the technology covered by the
Patent or seek investors or entities for a joint venture or licensing agreement.
There can be no assurances that Bio-Medical will be able to find a commercial
application for the technology covered by the Patent or a viable alternative to
exploiting the Patent. Even if Bio-Medical is able to develop a commercial
application for the technology covered by the Patent, there can be no assurances
that they will be able to successfully market such application.

Bio-Medical expects to encounter competition from other entities in the medical
device business with technology similar to that covered by the Patent. Many of
these entities, including large drug and medical companies, bio-technology
companies, venture capital partnerships and corporations, blind pool companies,
large industrial and financial institutions, small business investment companies
and wealthy individuals, are well-established and have extensive experience in
connection with developing and exploiting medical technology and devices. Many
of these competitors possess greater financial, technical, human and other
resources than Bio-Medical and there can be no assurance that Bio-Medical will
have the ability to compete successfully. Bio-Medical's financial resources will
be limited in comparison to those of many of its competitors. There can be no
assurance that such prospects will permit Bio-Medical to achieve its stated
business objectives.

Bio-Medical has never derived any revenues from the Patent. There can be no
assurances that Bio-Medical will be able to successfully exploit the Patent or
market the technology covered by the Patent or that Bio-Medical will ever derive
any revenues from the Patent or the technology covered by the Patent.

Description of Property

Since January 5, 2004, Bio-Medical has maintained its principal offices at 100
Mill Plain Road, Danbury, Connecticut 06811. The Company is using a portion of
the premises occupied by Catalyst Financial LLC, a full service brokerage,
investment banking and consulting firm, located at 100 Mill Plain Road, Danbury,
Connecticut 06811. Steven N. Bronson, the President of Bio-Medical, is the
principal and owner of Catalyst Financial LLC. Catalyst Financial LLC has agreed
to waive the payment of any rent by Bio-Medical for use of the offices.

Prior to January 5, 2004, Bio-Medical used a portion of the premises located at
10 South Street, Suite 202, Ridgefield, Connecticut 06877, occupied by Catalyst
Financial LLC. Bio-Medical did not pay any rent to Catalyst Financial LLC for
the use of the offices located at 10 South Street, Suite 202, Ridgefield,
Connecticut 06877.

Bio-Medical's Directors and Executive Officers

The following table sets forth certain information concerning Bio-Medical's
directors and executive officers, including employment history and any
directorships held in public companies;

Name Age Position
- ----------------- --- --------------------------------------------
Steven N. Bronson 41 Chairman, President, Treasurer and Secretary
Alan Rosenberg 36 Director
Louis Meade 50 Director

Steven N. Bronson has served as a director of Bio-Medical since March 3, 2003.
Mr. Bronson is also a director of Ridgefield. Mr. Bronson is also the President
of Catalyst Financial LLC, a privately held full service securities brokerage
and investment banking firm. Mr. Bronson has held that position since September
24, 1998. During the period of 1991 through September 23, 1998, Mr. Bronson was
President of Barber & Bronson Incorporated, a full service securities brokerage
and investment banking firm. In addition, Mr. Bronson is an officer and director
of 4net Software, Inc., a publicly traded corporation.

Alan Rosenberg has served as a director of Bio-Medical since January 31, 2006.
Mr. Rosenberg currently serves as an Agency Chief Information Officer for the
City of New York's Department of Small Business Services. Prior to that, he was
a Director in the Office of the CIO for the Department of Information Technology
and Telecommunications for the City of New York. He also served as the Deputy
Director of Management Information Systems (MIS) for the City of New York,
Office of the Mayor. Mr. Rosenberg graduated from Polytechnic University with a
MS in the Management of Technology and holds a BA from Ohio State University. In
addition, Mr. Rosenberg is a director of 4net Software, Inc., a publicly traded
corporation.

Louis Meade has served as a director of Bio-Medical since January 31, 2006. Mr.
Meade has extensive experience in the development, funding and operation of
small businesses. Mr. Meade is currently the Chairman and Chief Executive
Officer of Private Company Marketplace, Inc., which offers a centralized
information clearinghouse and trading platform for Accredited Investors who have
invested in private companies. Mr. Meade brings over twenty-five years
experience in private and public companies. Mr. Meade was a founding member and
investor in Anthrogenesis, Inc., a company which was sold to Celgene
(CELG-Nasdq) in 2002 for $ 70 million dollars. In his dealings with public
companies Mr. Meade had worked for the American Stock Exchange for three years
and was responsible for listing companies on the American Stock Exchange. He is
Series 7 and Series 63 registered. Mr. Meade has also worked on numerous
offerings. Mr. Meade holds an M.B.A. from Pace University and has a B.B.A. from
Benard M. Baruch College.

No director, executive officer, promoter or control person of Bio-Medical has,
within the last five years: (i) had a bankruptcy petition filed by or against
any business of which such person was a general partner or executive officer
either at the time of the bankruptcy or within two years prior to that time;
(ii) been convicted in a criminal proceeding or is currently subject to a
pending criminal proceeding (excluding traffic violations or similar
misdemeanors); (iii) been subject to any order, judgment or decree, not
subsequently reversed, suspended or vacated, of any court of competent
jurisdiction, permanently or temporarily enjoining, barring, suspending or
otherwise limiting his involvement in any type of business, securities or
banking activities; (iv) been found by a court of competent jurisdiction (in a
civil action), the Securities and Exchange Commission (the "Commission") or the
Commodity Futures Trading Commission to have violated a federal or state
securities or commodities law, and the judgment has not been reversed, suspended
or vacated. There are no family relationships among any directors and executive
officers of the Subsidiary.

Indemnification of Bio-Medical's Directors and Officers

Bio-Medical's Articles of Incorporation provide for indemnification of
Bio-Medical officers and directors to the full extent permitted by Nevada law,
which generally permits indemnification for actions taken by officers or
directors as Bio-Medical representatives if the officer or director acted in
good faith and in a manner he or she reasonably believed to be in the best
interest of the corporation.

As permitted under Nevada law, the by-laws contain a provision eliminating the
personal liability of directors to Ridgefield and/or Bio-Medical shareholders
for monetary damages for any action taken, except for breaches of, or failure to
perform their fiduciary duties, and such breach or failure constituted
self-dealing, willful misconduct or recklessness. The applicable provisions of
Nevada law pertain only to breaches of duty by directors as directors and not in
any other corporate capacity, including as officers. As a result of the
inclusion of these provisions, shareholders may be unable to recover monetary
damages against directors for actions taken by them which in violation of their
fiduciary duties and are not the result of self-dealing, willful misconduct or
recklessness, although it may be possible to obtain injunctive or other
equitable relief with respect to such actions. If equitable remedies are found
not to be available to shareholders in any particular case, shareholders may not
have any effective remedy against the challenged conduct.

Committees of Bio-Medical's Board Of Directors

Bio-Medical's Board of Directors does not have any committees.

Bio-Medical's Executive and Director Compensation

Bio-Medical has never paid any compensation it is directors.

Bio-Medical has never paid any compensation to its officers. Bio-Medical has not
entered into any employment agreements. Steven N. Bronson, the Chairman and
President of the Ridgefield is the sole officer of Bio-Medical without any
salary or written employment agreement.

Bio-Medical's Dividend Policy

Payment of future cash dividends, if any, will be at the discretion of
Bio-Medical Board of Directors in accordance with applicable law after taking
into account various factors, including Bio-Medical's financial condition,
operating results, current and anticipated cash needs, plans for expansion and
contractual restrictions with respect to the payment of dividends.

Capitalization of Bio-Medical

Bio-Medical is authorized to issue of 45,000,000 shares of capital stock,
consisting of 40,000,000 shares of common stock, par value $.001 per share and
5,000,000 shares of preferred stock, par value $.01 per share. Immediately prior
to the Spin-off, Bio-Medical will have 1,140,773 shares of common stock, par
value $.001 per share issued and outstanding, and no shares of preferred stock
issued and outstanding. All of the shares of Bio-Medical common stock issued and
outstanding prior to the Spin-off will be owned by Ridgefield.

Immediately following the Spin-off, Bio-Medical will have 1,140,773 shares of
common stock, par value $.001 per share issued and outstanding, and no shares of
preferred stock issued and outstanding. After the Spin-off the shares of
Bio-Medical common stock will be owned by the shareholders of Ridgefield.

Common Stock

The holders of Bio-Medical common stock will be entitled to one vote for each
share on all matters voted on by shareholders, including elections of directors,
and, except as otherwise required by law or provided in any resolution adopted
by Bio-Medical's Board of Directors with respect to any series of preferred
stock, the holders of such shares will possess all voting power. Subject to any
preferential rights of any outstanding series of Bio-Medical preferred stock
created by Bio-Medical's Board of Directors from time to time, the holders of
common stock will be entitled to such dividends as may be declared from time to
time by Bio-Medical's Board of Directors from funds available therefore and upon
liquidation will be entitled to receive pro rata the value of all assets
available for distribution to such holders.

The holders of Bio-Medical common stock will have no preemptive rights. The
rights, preferences and privileges of holders of common stock are subject to,
and may be adversely affected by, the rights of the holders of shares of any
series of preferred stock which Bio-Medical may designate and issue in the
future. All outstanding shares of Bio-Medical common stock are, and after the
Spin-off will continue to be, fully paid and non-assessable.

Preferred Stock

Under the Articles of Incorporation, the Board of Directors of Bio-Medical has
the authority, without further action by shareholders, to issue up to 5,000,000
shares of preferred stock. Bio-Medical's Board of Directors may issue preferred
stock in one or more series and may determine the rights, preferences,
privileges, qualifications and restrictions granted to or imposed upon the
preferred stock, including dividend rights, conversion rights, voting rights,
rights and terms of redemption, liquidation preferences and sinking fund terms,
any or all of which may be greater than the rights of the common stock. The
issuance of preferred stock could adversely affect the voting power of holders
of common stock and reduce the likelihood that common shareholders will receive
dividend payments and payments upon liquidation. The issuance of preferred stock
could also have the effect of decreasing the market price of the common stock
and could delay, deter or prevent a change in control of Bio-Medical.
Bio-Medical has no present plans to issue any shares of preferred stock.

Market Price

There is no present market for the securities of Bio-Medical and there can be no
assurances that a market will develop for the securities of Bio-Medical.
Bio-Medical plans on filing a registration statement with the U.S. Securities
and Exchange Commission on Form 10-SB to register the issued and outstanding
shares of Bio-Medical under the Securities Exchange Act of 1934. While
Bio-Medical intends to use its best efforts to have the registration statement
declared effective, there can be no assurances that the registration statement
will be declared effective.

There have been no sales of the Bio-Medical common stock prior to the Spin-off.
Since Bio-Medical was incorporated on March 3, 2003, Ridgefield has been the
only shareholder of Bio-Medical.

Bio-Medical's Transfer Agent

Atlas Stock Transfer Corporation is the transfer agent for the securities of
Bio-Medical.

Pro Forma Financial Statements for Bio-Medical

Prior to the Spin-off Date the financial statements of the Bio-Medical are
consolidated with the financial statements of Ridgefield. Readers are referred
to the audited financial statements for Ridgefield for the year ended December
31, 2005 that are included in Ridgefield's Annual Report on Form 10-KSB for the
year ended December 31, 2005 which accompanies this Information Statement. The
following un-audited pro forma financial statements for Bio-Medical are
qualified by reference to Ridgefield's audited financial statements and the
notes to Ridgefield's audited financial statements.

BIO-MEDICAL AUTOMATION, INC.
PROFORMA BALANCE SHEET

May 10, 2006
(Unaudited)
ASSETS

CURRENT ASSETS

Cash $ 50,100
-----------
Total Assets $ 50,100
===========

LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITIES

Accounts payable and accrued expenses $ -
-----------
Total Liabilities $ -
-----------

STOCKHOLDERS' EQUITy
Preferred Stock, $.01 par value; authorized - 5,000,000 shares
Issued and outstanding - none -
Common Stock, $.001 par value; authorized - 30,000,000 shares
Issued and outstanding - 1,140,773 18,724
Capital in excess of par value 50,000
Retained Deficit (18,624)
----------
50,100
----------
$ 50,100
==========

BIO-MEDICAL AUTOMATION, INC.
PROFORMA
STATEMENTS OF OPERATIONS
(UNAUDITED)

May 10, 2006 June 30, 2003
to
May 10, 2006

REVENUES

Interest income $ 123 $ 123
--------- ---------
Total Income 123 123

OPERATING EXPENSES
General & Administrative 23 23
Patent write-off -- 18,724
--------- ---------
Total Operating Expenses -- 18,747
--------- ---------

Net Operating gain (loss) $ 100 $ (18,624)
========= =========

BIO-MEDICAL AUTOMATION, INC.
PROFORMA
STATEMENT OF CASH FLOWS
(Unaudited)

Cumulative
Amounts from
May 10, 2006 June 30, 2003
to
May 10, 2006

CASH FLOWS FROM OPERATING ACTIVITIES
Net Income $ 100 $ 100
Adjustment to reconcile net loss
to net cash used in operating
activities
Write-off of patent -- 18,724
-------- --------
Net cash provided by (used in)
operating activities 100 (18,624)

CASH FLOWS FROM FINANCING ACTIVITIES
Capital Contributed from Ridgefield
Acquisition Corp. 50,000 50,000
-------- --------
Net cash provided by financing
activities 50,000 50,000

NET (INCREASE) DECREASE IN CASH 50,100 50,100

CASH, BEGINNING OF PERIODS -- --
-------- --------

CASH, END OF PERIODS $ 50,100 $ 50,100
======== ========

BIO-MEDICAL AUTOMATION, INC.
PROFORMA
STATEMENTS OF STOCKHOLDERS' EQUITY
DECEMBER 31, 2003 to MAY 10, 2006

Common Stock Capital in Accumulated Total
------------------- Excess of Earnings Stockholder's
Shares Amount Par Value (Deficit) Equity

Balance, December 31, 2003 5,000,000 $18,724 $ -- ($ 18,724) --
--------- ------- --------- --------- ---------

2004 Activity -- -- -- -- --
--------- ------- --------- --------- ---------

Balance, December 31, 2004 5,000,000 $18,724 $ -- ($ 18,724) --
========= ======= ========= ========= =========

Investment by Ridgefield
Acquisition Corp. -- -- 50,000 -- 50,000

Surrender of shares by
Ridgefield Acquisition Corp. (3,859,227) -- -- -- --

Net Income for period ended
May 10, 2006 -- -- -- 100 100
--------- ------- --------- --------- ---------

Balance, May 10, 2006 1,140,773 $18,724 $ 50,000 ($ 18,624) ($ 50,100)
========= ======= ========= ========= =========

RISK FACTORS RELATING TO BIO-MEDICAL AND THE SPIN-OFF

An investment in Bio-Medical common stock involves risk. You should carefully
consider the following risk factors and all the other information contained in
this information statement in evaluating Bio-Medical's business plans and
Bio-Medical's common stock. Any of the following risks, if realized, could have
a material adverse effect on the value of Bio-Medical's common stock.

Risk Relating to Bio-Medical's Business Plan

Bio-Medical's primary asset is the Patent. For a description of the Patent read
the section "Description of Bio-Medical's Business," above. Bio-Medical's main
business objective is to either develop the Patent and market products derived
from the Patent or license the Patent to other businesses for use and
development.

Bio-Medical hopes to either raise capital to pursue the development of the
Patent or seek to find entities interested in the Patent for either a joint
venture or licensing of the Patent. Bio-Medical believes the Patent offers a
unique opportunity for the creation of devices for micro-manipulation in the
bio-medical and bio-technical fields. Because of limited resources available to
Bio-Medical, Bio-Medical has not been able to complete a more detailed analysis
of the market potential for the Patent or potential competition.

Bio-Medical has no operating history upon which you can evaluate Bio-Medical's
current or future performance. Accordingly, there can be no assurance that
Bio-Medical's business strategy will be successful on a long-term basis.
Bio-Medical may not be able to exploit the Patent as planned and may never be
profitable. If Bio-Medical's business plans are not successful, Bio-Medical may
not be able to continue operations as a going concern and Bio-Medical's
shareholders may lose their entire investment in Bio-Medical.

Certain of Bio-Medical's competitors may have greater resources, or they may
acquire greater resources. One or more of Bio-Medical's competitors may develop
technologies and products that are more effective or which may cost less, or
could potentially render Bio-Medical's patent noncompetitive or obsolete.

Following the Spin-off, Bio-Medical will seek to operate as a separate company.
Bio-Medical has implemented procedures to support its current and future
business plan, and its responsibilities as a company. However, these procedures
may be inadequate and Bio-Medical may be required to develop or otherwise
acquire other systems and infrastructure, or to obtain certain corporate
services from Ridgefield, to support its current and future business plan.
Bio-Medical may incur costs and expenses greater than those that Bio-Medical
currently incurs as a result of Bio-Medical's separation from Ridgefield. These
increased costs and expenses may arise from various factors, including financial
reporting, costs associated with complying with federal securities laws
(including compliance with the Sarbanes-Oxley Act of 2002), tax administration,
attorney's fees and third-party related agreements.

Bio-Medical plans to exploit the Patent which may require funds in excess of its
available cash and may require Bio-Medical to seek financing from third parties.
In the past, Ridgefield has provided capital for Bio-Medical's general corporate
purposes. After the Spin-off, Ridgefield will not provide funds to Bio-Medical.
Without the opportunity to obtain financing from Ridgefield, Bio-Medical may in
the future need to obtain additional financing from banks, or through public
offerings or private placements of debt or equity securities, strategic
relationships or other arrangements. If Bio-Medical raises funds through the
issuance of equity, any preferred stock issued will have rights, preferences and
privileges senior to those of holders of Bio-Medical common stock in the event
of liquidation. If Bio-Medical raises funds through the issuance of equity, the
issuance would dilute your ownership interest.

Bio-Medical Has Limited Resources

Bio-Medical has limited resources and has never had any revenues from
operations. Bio-Medical will only earn revenues through the successful
exploitation of the Patent. There can be no assurance that Bio-Medical will
derive any revenues from the Patent. The current revenues of Bio-Medical may not
be sufficient to fund the successful development and exploitation of the Patent.
Based on Bio-Medical's limited resources, Bio-Medical may not be able to
effectuate its business plan to exploit the Patent. There also can be no
assurance that determinations ultimately made by Bio-Medical will permit
Bio-Medical to achieve its business objectives.

Bio-Medical May Need Additional Financing in Order to Execute Its Business Plan

Bio-Medical cannot ascertain with any degree of certainty the capital
requirements for the execution of its business plan. In the event that
Bio-Medical's limited financial resources prove to be insufficient to develop
and exploit the Patent, Bio-Medical may need to seek debt or equity financing.
There can be no assurances that Bio-Medical will be able to obtain additional
financing.

Additional Financing May Not Be Available to Bio-Medical

There can be no assurance that additional financing will be available to
Bio-Medical on acceptable terms, or at all. To the extent that additional
financing proves to be unavailable when needed, Bio-Medical would be limited in
its attempts to successfully develop and exploit the Patent. Bio-Medical has no
arrangements with any bank or financial institution to secure financing and
there can be no assurance that any such arrangement, if required or otherwise
sought, would be available on terms deemed to be commercially acceptable and in
the best interests of Bio-Medical.

Bio-Medical May Not Be Able to Borrow Funds

While there currently are no limitations on Bio-Medical's ability to borrow
funds, the limited resources of Bio-Medical and limited operating history will
make it difficult to borrow funds. The amount and nature of any borrowings by
Bio-Medical will depend on numerous considerations, including Bio-Medical's
capital requirements, Bio-Medical's perceived ability to meet debt service on
any such borrowings and the then prevailing conditions in the financial markets,
as well as general economic conditions. There can be no assurance that debt
financing, if required or sought, would be available on terms deemed to be
commercially acceptable by and in the best interests of Bio-Medical. The
inability of Bio-Medical to borrow funds required to effect or facilitate
Bio-Medical's business plan may have a material adverse effect on Bio-Medical's
financial condition and future prospects. Additionally, to the extent that debt
financing ultimately proves to be available, any borrowings may subject
Bio-Medical to various risks traditionally associated with indebtedness,
including the risks of interest rate fluctuations and insufficiency of cash flow
to pay principal and interest.

Uncertain Prospects of Technology Covered by Patent

Bio-Medical has never derived any revenues from the technology covered by the
Patent and there can be no assurances that Bio-Medical will be able to derive
any revenues from the exploitation of the Patent. Bio-Medical will attempt to
research and develop a commercial application for the technology covered by the
Patent. However there can be no assurances that Bio-Medical will be able to find
a commercial application for the technology covered by the Patent. Even if
Bio-Medical is able to develop a commercial application for the technology
covered by the Patent, there can be no assurances that Bio-Medical will be able
to successfully market such application.

Competition for the Patent

If Bio-Medical is not able to protect its intellectual
property rights, it may not be able to compete as effectively

Bio-Medical possesses intellectual property rights in the Patent, including
trademarks, copyrights, and applications for the above, as well trade secrets,
manufacturing know-how, and other proprietary information. The intellectual
property rights are sometimes subject to infringement or misappropriation by
other organizations, and failing an amiable resolution, Bio-Medical may be
forced to resort to legal proceedings to protect its rights in such intellectual
property.

Steven N. Bronson is Critical to the Future Success of Bio-Medical

Steven N. Bronson is the Chairman, C.E.O. and President of Bio-Medical. The
ability of Bio-Medical to successfully carry out its business plan develop and
exploit the Patent will be dependent upon the efforts of Mr. Bronson and
Bio-Medical's directors. Notwithstanding the significance of Mr. Bronson,
Bio-Medical has not obtained any "key man" life insurance on his life. The loss
of the services of Mr. Bronson could have a material adverse effect on
Bio-Medical's ability to successfully achieve its business objectives. If
additional personnel are required, there can be no assurance that Bio-Medical
will be able to retain such necessary additional personnel.

Mr. Bronson Has Effective Control of Bio-Medical's Affairs

After the completion of the Spin-off, Mr. Bronson will own 826,116 shares of
common stock of Bio-Medical, representing approximately 72% of the issued and
outstanding shares of common stock and approximately 72% of the voting power of
the issued and outstanding shares of common stock of Bio-Medical. In the
election of directors, stockholders are not entitled to cumulate their votes for
nominees. Accordingly, as a practical matter, Mr. Bronson may be able to elect
all of Bio-Medical's directors and otherwise direct the affairs of Bio-Medical.

There Exist Conflicts of Interest Relating to
Mr. Bronson's Time Commitment to Bio-Medical

Mr. Bronson is not required to commit his full time to the affairs of
Bio-Medical. Mr. Bronson will have conflicts of interest in allocating
management time among various business activities. As a result, the business of
Bio-Medical may be compromised. However, Mr. Bronson will devote such time as he
deems reasonably necessary to carry out the business and affairs of Bio-Medical.
Mr. Bronson provides critical leadership and direction to Bio-Medical, and his
experience and expertise cannot be easily duplicated or replaced. Bio-Medical
does not maintain any key-person life insurance policies. The loss of any of its
senior management could seriously harm its business.

There Exist Risks to Stockholders Relating to Dilution:
Authorization of Additional Securities

Bio-Medical's Articles of Incorporation authorizes the issuance of 40,000,000
shares of common stock. Following the completion of the Spin-off, Bio-Medical
will have 1,140,773 shares of common stock issued and outstanding and 38,859,227
authorized but unissued shares of common stock available for issuance. Although
Bio-Medical has no commitments as of this date to issue its securities,
Bio-Medical will, in all likelihood, issue a substantial number of additional
shares in connection with or following a financing or other transaction. To the
extent that additional shares of common stock are issued, Bio-Medical's
stockholders would experience dilution of their ownership interests in
Bio-Medical. Bio-Medical may use consultants and other third parties providing
goods and services. These consultants or third parties may be paid in cash,
stock, options or other securities of Bio-Medical. Bio-Medical may in the future
need to raise additional funds by selling securities of Bio-Medical which may
involve substantial additional dilution to the investors.

Bio-Medical is Authorized to Issue Preferred Stock

Bio-Medical's Articles of Incorporation authorizes the designation and issuance
of 5,000,000 shares of preferred stock (the "Preferred Stock"), with such
designations, powers, preferences, rights, qualifications, limitations and
restrictions of such series as the Board of Directors, subject to the laws of
the State of Nevada, may determine from time to time. Accordingly, the Board of
Directors is empowered, without stockholder approval, to designate and issue
Preferred Stock with dividend, liquidation, conversion, voting or other rights
which could adversely affect the voting power or other rights of the holders of
common stock. In addition, the Preferred Stock could be utilized, under certain
circumstances, as a method of discouraging, delaying or preventing a change in
control. Although Bio-Medical does not currently intend to designate or issue
any shares of Preferred Stock, there can be no assurance that Bio-Medical will
not do so in the future. It is likely however, that following a merger, new
management may issue such preferred stock, and it is possible that one or more
series of preferred stock will be designated and/or issued in order to
effectuate a merger or financing. As of this date, Bio-Medical has no
outstanding shares of Preferred Stock and has not designated the rights or
preferences of any series of preferred stock.

Conflicts of Interest

Bio-Medical will have potential conflicts of interest with Ridgefield after the
Spin-off. Bio-Medical has overlapping directors and management with Ridgefield
which may lead to conflicting interests. For example, at the time of the
Spin-off, Steven N. Bronson will be serving on the board of directors of both
Ridgefield and Bio-Medical. Mr. Bronson will owe fiduciary duties to both
company's shareholders. Therefore, such persons may have conflicts of interest
or the appearance of conflicts of interest with respect to matters involving or
affecting each company. Moreover, after the Spin-off, most of the directors and
officers will continue to own stock in both companies which they acquired prior
to the Spin-off. These ownership interests could create, or appear to create,
potential conflicts of interest when these individuals are faced with decisions
that could have different implications for Bio-Medical and Ridgefield.

Certain adverse tax consequences could arise by reason of the Spin-off

Ridgefield and its Board of Directors has structured the Spin-off to qualify as
a tax-free spin-off to its shareholders under Section 355 of the Internal
Revenue Code of 1986, however there can be no assurances that the IRS will not
determine that the Spin-off does not qualify as a tax free treatment.
Accordingly, it is possible that Bio-Medical shareholders could recognize a
taxable gain if the IRS were to assert that the Spin-off was taxable. See "U.S.
Federal Income Tax Consequences of the Spin-off."

Risks Relating to Ownership of Bio-Medical's Common Stock

The stock issued in the Spin-off will be restricted stock and not publicly
traded and as such will bear a restrictive legend. Bio-Medical's common stock
has no prior public market and Bio-Medical cannot predict the price range in
which it will trade if and when it does start trading in the future.

There is no present market for the securities of Bio-Medical and there can be no
assurances that a market will develop for the securities of Bio-Medical.
Bio-Medical intends on filing a registration statement with the U.S. Securities
and Exchange Commission on Form 10-SB to register the issued and outstanding
shares of Bio-Medical common stock under the Securities Exchange Act of 1934.
While Bio-Medical intends to use its best efforts to have the registration
statement declared effective, there can be no assurances that the registration
statement will be declared effective.

Since there has never been a trading market for the shares of Bio-Medical's
common stock, there can be no assurance as to the price at which Bio-Medical's
common stock will trade. The securities of many companies have experienced
extreme price and volume fluctuations in recent years, often unrelated to the
companies' operating performance. Accordingly, Bio-Medical cannot predict
whether the market price of Bio-Medical's common stock will be volatile.

It is likely that Bio-Medical will have little or no quarterly revenues and
operating results may vary significantly in the future. It is also possible that
in some future quarters, Bio-Medical's revenues and operating results will fall
below Bio-Medical's expectations or the expectations of investors. If
Bio-Medical does not meet these expectations, the price of Bio-Medical's common
stock may decline significantly.

Bio-Medical Expects to Pay No Cash Dividends

Bio-Medical presently does not expect to pay dividends. The payment of
dividends, if any, will be contingent upon Bio-Medical's revenues and earnings,
if any, capital requirements, and general financial condition. The payment of
any dividends will be within the discretion of Bio-Medical's then Board of
Directors. Bio-Medical presently intends to retain all earnings, if any, to
implement its business plan, accordingly, the Board of Directors does not
anticipate declaring any dividends in the foreseeable future.

Investors Should Not Rely on Forward-Looking
Statements Because They Are Inherently Uncertain

This document contains certain forward looking statements that involve risks and
uncertainties. We use words such as "anticipate," "believe," "expect," "future,"
"intend," "plan," and similar expressions to identify forward-looking
statements. These statements are only predictions. Although we believe that the
expectations reflected in these forward-looking statements are reasonable, we
cannot guarantee future results, levels of activity, performance or
achievements. You should not place undue reliance on these forward-looking
statements, which apply only as of the date of this document. Our actual results
could differ materially from those anticipated in these forward-looking
statements for many reasons, including the risks faced by us and described on
the preceding pages and elsewhere in this document.

We believe it is important to communicate our expectations to our investors.
However, there may be events in the future that we are not able to predict
accurately or over which we have no control. The risk factors listed above, as
well as any cautionary language in this document, provide examples of risks,
uncertainties and events that may cause our actual results to differ materially
from the expectations we describe in our forward-looking statements. Before you
invest in our common stock, you should be aware that the occurrence of the
events described in these risk factors and elsewhere in this document could have
a material adverse effect on our business, operating results, financial
condition and stock price.

Description of the Spin-Off

General

Given the evolution of the distinct and highly competitive environments in which
Ridgefield and Bio-Medical operate, Ridgefield believes the best way to enhance
the success and maximize shareholder value of both companies over the long term
is to enable each one to pursue its unique and focused strategy. After the
Spin-off, Ridgefield will continue to focus on its acquisition strategy and
Bio-Medical will focus on the development and exploitation of the Patent.

Ridgefield has declared a stock dividend, whereby each Ridgefield shareholder
will receive one share of Bio-Medical common stock for each share of Ridgefield
common stock held by the Ridgefield shareholder on April 28, 2006, the Record
Date. The issuance of the stock dividend will effect the Spin-off of 100% of
Bio-Medical common stock to Ridgefield shareholders on a pro rata basis. The
dividend distribution will be effective no sooner than 20 days after the mailing
of this Information Statement to the shareholders of Ridgefield and the date
that Bio-Medicl's registration statement on Form 10-SB is declared effective by
the U.S. Securities and Exchange Commission. Ridgefield anticipates mailing this
Information Statement to our shareholders on May 30, 2006.

Manner of Effecting the Spin-off

Ridgefield's Board of Directors approved the Spin-off and declared the stock
dividend at a meeting of the Board Directors on April 18, 2006. As a result of
the Spin-off, each Ridgefield shareholder of record as of April 28, 2006 will
receive one share of Bio-Medical common stock for every one share of Ridgefield
common stock owned by such shareholders as of the Record Date. In order to be
entitled to receive shares of Bio-Medical common stock in the Spin-off,
Ridgefield shareholders must be shareholders at the close of regular business of
the NASDAQ Over-the-Counter Bulletin Board on the Record Date.

Pursuant to the Spin-off, Ridgefield shareholders will receive stock
certificates representing their shares of Bio-Medical common stock. The shares
of Bio-Medical common stock being issued as a special stock dividend by
Ridgefield pursuant to the Spin-off have not been registered under the
Securities Act of 1933 and all of the stock certificates representing such
securities will bear a restrictive legend in the form as set forth below:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933. THESE SECURITIES MAY NOT BE OFFERED,
SOLD, TRANSFERRED, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933
OR AN OPINION OF COUNSEL SATISFACTORY TO BIO-MEDICAL AUTOMATION, INC. THAT
REGISTRATION IS NOT REQUIRED UNDER SAID ACT.

Ridgefield shareholders will NOT be required to pay for shares of Bio-Medical
common stock received pursuant to the Spin-off or to surrender or exchange
shares of Ridgefield common stock in order to receive the shares of Bio-Medical
common stock or to take any other action in connection with the Spin-off.

No vote of Ridgefield shareholders is required or sought in connection with the
Spin-off.

Reasons for the Spin-off

Ridgefield's Board of Directors has determined that separating Bio-Medical from
Ridgefield's other businesses in the form of a tax-free spin-off to Ridgefield
shareholders of Bio-Medical common stock is appropriate and advisable for
Ridgefield and its shareholders. Ridgefield's Board of Directors believes that
Bio-Medical separation from Ridgefield will provide both companies with the
opportunity to focus exclusively on their respective businesses. In addition,
the separation will enable each company to enhance its strategic, financial and
operational flexibility, particularly by opening financing opportunities in
exploiting the Patent.

Ridgefield's Board of Directors considered a number of other factors in
evaluating the Spin-off, including the reaction of Ridgefield shareholders to
the Spin-off and the one-time and on-going costs of the Spin-off. Ridgefield's
Board of Directors concluded that the potential benefits of the separation
outweigh these factors, and that separating Bio-Medical from Ridgefield's other
businesses in the form of a tax-free Spin-off to Ridgefield shareholders is
appropriate and advisable for Ridgefield and its shareholders.

Results of the Spin-off

After the Spin-off, Bio-Medical will be a separate company. Immediately after
the Spin-off, Bio-Medical expects to have approximately 660 record and
beneficial shareholders of Bio-Medical common stock, and 1,140,773 shares of
Bio-Medical common stock, par value $.001 per share, issued and outstanding.
This figure reflects all options exercised by Ridgefield officers prior to the
record date of the Spin-off for the purchase of Ridgefield common stock.

Bio-Medical Relationship with Ridgefield after the Spin-off

Following the Spin-off, Bio-Medical will be an independent company, and
Ridgefield will not have any stock ownership interest in Bio-Medical.

Registration of the Securities of Bio-Medical

The securities of Bio-Medical Automation, Inc. being issued to Ridgefield's
shareholders as a stock dividend pursuant to the Spin-off are restricted
securities that have not been registered with the U.S. Securities and Exchange
Commission and/or any state securities regulator. The stock certificate
representing your shares of Bio-Medical common stock issued to Ridgefield
shareholders pursuant to the stock dividend will bear a restrictive legend that
states that the shares of Bio-Medical common stock have not be registered under
the Securities Act of 1933 and that such shares may not be assigned, sold,
transferred or conveyed absent registration or an exemption from registration.

There is no public market for Bio-Medical common stock and there can be no
assurance that a market will develop for the shares of Bio-Medical common stock.

In conjunction with the Spin-off,+
+ Bio-Medical will file a registration statement
with the U.S. Securities and Exchange Commission on Form 10-SB to register the
shares of Bio-Medical common stock issued pursuant to the Spin-off. The special
stock dividend of Bio-Medical common stock will be issued after Bio-Medical's
registration statement on Form 10-SB is declared effective and at least 20 days
after this Information Statement has been mailed to Ridgefield's shareholders.
There can be no assurance that the registration statement will be declared
effective.

Dissenters' Rights

Ridgefield shareholders have no dissenters' rights or appraisal rights in
connection with the Spin-off.

U.S. Federal Income Tax Consequences of Spin-off

Ridgefield has not received a legal opinion as to the federal income tax
treatment of the Spin-off. The Board of Directors' believe that the Spin-off
will qualify as a transaction described in Section 355(a) of the Internal
Revenue Code. There can be no assurance that the Spin-off will qualify for
tax-free treatment under Section 355(a) of the Internal Revenue Code.

If the Spin-off were not to qualify as tax-free to Ridgefield shareholders, each
Ridgefield shareholder who receives Bio-Medical common stock in the Spin-off
would be treated as if such shareholder received a taxable dividend equal to the
value of Bio-Medical common stock received in the Spin-off. If the Spin-off were
not to qualify as tax-free to Ridgefield, a corporate level capital gains tax
would be payable by Ridgefield based upon the difference between the fair market
value of the stock distributed and Ridgefield's adjusted basis in the stock.

Assuming the Spin-off qualified as tax-free under Section 355 of the Internal
Revenue Code no income gain or loss will be recognized by a Ridgefield
shareholder as a result of the Spin-off. The aggregate basis of a shareholder's
Ridgefield common stock and Bio-Medical common stock immediately after the
Spin-off will be the same as the basis of the shareholder's Ridgefield common
stock immediately before the Spin-off, allocated between Bio-Medical's common
stock and Ridgefield's common stock in proportion to their relative fair market
values.

U.S. Treasury regulations require each Ridgefield shareholder that receives
Bio-Medical stock in the Spin-off to attach to the shareholder's U.S. federal
income tax return for the year in which the Spin-off occurs a detailed statement
setting forth information as may be appropriate to show the applicability of
Section 355 of the Internal Revenue Code. Ridgefield will provide Ridgefield
shareholders who receive Bio-Medical stock in the Spin-off with the information
necessary to comply with this requirement.

Assuming the Spin-off qualified as tax-free under Section 355 of the Internal
Revenue Code, no material amount of gain or loss will be recognized by either
Ridgefield or Bio-Medical as a result of the Spin-off.

The summary of the U.S. federal income tax consequences of the Spin-off set
forth above does not address the U.S. federal income tax consequences that may
apply to shareholders that are not U.S. holders and does not address all of the
U.S. federal income tax consequences of U.S. holders that are subject to special
treatment under the internal revenue code.

RIDGEFIELD SHAREHOLDERS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS TO DETERMINE
THE PARTICULAR TAX CONSEQUENCES OF THE SPIN-OFF TO THEM, INCLUDING THE EFFECT OF
ANY STATE, LOCAL OR FOREIGN INCOME AND OTHER TAX LAWS.

Certain benefits of the Spin-off include:

Sharper Strategic Focus; Allocation of Capital Resources

We anticipate that the Spin-off will allow each company to focus exclusively on
the unique opportunities facing its respective business. In addition, each
company can devote more management time and attention toward meeting the unique
needs of its respective goals. We believe this focused approach will allow each
management team to make decisions more quickly and efficiently.

Greater Market Recognition of Bio-Medical Value

Ridgefield's Board of Directors believes that by standing as a separate entity
Bio-Medical will be able to have direct access to capital. By eventually
becoming a public company, Bio-Medical hopes to have a greater visibility in the
equity markets through a simpler business model. This greater visibility could
improve Bio-Medical's opportunities to obtain financing and lead to a greater
valuation of Bio-Medical than may otherwise be accorded to it as a wholly owned
subsidiary of Ridgefield.

Use of Bio-Medical Stock for Acquisitions

In the future, there may be opportunities for Bio-Medical to expand its
strategic business through the acquisition of one or more complimentary
businesses. There can be no assurance that at the time of the prospective
acquisition that Bio-Medical would have the access to capital or resources to
finance such an acquisition exclusively through its own reserves, through the
issuance of equity securities or through debt financing. Bio-Medical may also
have the flexibility of acquiring other businesses with its own capital stock,
through debt financing, or through a combination of the two financing
alternatives.

Reason for Furnishing this Information Statement

This Information Statement is being furnished solely to provide information to
Ridgefield shareholders who will receive shares of Bio-Medical common stock in
the Spin-off. It is not and is not to be construed as an inducement or
encouragement to buy or sell any of Bio-Medical securities. We believe that the
information contained in this Information Statement is accurate as of the date
set forth on the cover. Changes may occur after that date and neither Ridgefield
nor Bio-Medical undertake any obligation to update the information except in the
normal course of Bio-Medical's respective public disclosure obligations.

AVAILABLE INFORMATION

If you have any questions about Ridgefield, the Spin-off and/or Bio-Medical, you
may contact Ridgefield Acquisition Corp., Attn: Steven N. Bronson, at 100 Mill
Plain Road, Danbury, Connecticut 06811.

Ridgefield is subject to the informational requirements of the Securities
Exchange Act of 1934 and in accordance with the requirements thereof, file
reports, proxy statements and other information with the Securities and Exchange
Commission ("SEC"). Copies of these reports, proxy statements and other
information can be obtained at the SEC's public reference facilities at
Judiciary Plaza, Room 1024, 450 Fifth Street, N.W., Washington, D.C., 20549.
Additionally, these filings may be viewed at the SEC's website at
http://www.sec.gov.

DOCUMENTS INCORPORATED BY REFERENCE

The following documents accompany this Information Statement and are
incorporated herein by reference:

1. Ridgefield's Annual Report on Form 10- KSB for the year ended December
31, 2005, including the financial statements as filed with the United
States Securities and Exchange Commission, accompanies this Information
Statement and is incorporated herein by reference.

2. Ridgefield's Notice of Special Meeting of Shareholders to be held on
June 16, 2006 and Proxy Statement, accompanies this Information
Statement and are incorporated herein by reference.

Any shareholder who has not received a copy of Ridgefield's Annual Report on
Form 10-KSB for the year ended December 31, 2005 and/or Ridgefield's Notice of
Special Meeting of Shareholders to be held on June 16, 2006 and Proxy Statement
and wishes to do so should direct a written request to the Company's President
by mail at 100 Mill Plain Road, Danbury, Connecticut 06811.

Any statement contained in a document incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded for purposes of
this Information Statement to the extent that a statement contained herein or in
any other subsequently filed document that also is, or is deemed to be,
incorporated by reference herein modifies or supersedes such statement. Any such
statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this Information Statement. This
Information Statement incorporates, by reference, certain documents that are not
presented herein or delivered herewith. Copies of any such documents, other than
exhibits to such documents which are not specifically incorporated by reference
herein, are available without charge to any person, including any shareholder,
to whom this Information Statement is delivered, upon written or oral request to
the Company's President by mail at 100 Mill Plain Road, Danbury, Connecticut
06811.

No person is authorized to give any information or to make any representations
other than those contained in this Information Statement, and, if given or made,
such information or representations must not be relied upon as having been
authorized. Neither the delivery of this Information Statement nor any Spin-off
of securities made hereunder shall imply that there has been no change in the
information set forth herein or in Bio-Medical affairs since the date hereof.

Dated: May 26, 2006
By Order of the Board of Directors

/s/ Steven N. Bronson

Steven N. Bronson, Chairman